◆ Market Terminal AILook up a stock

Xeris Biopharma Holdings, Inc. (XERS)

Healthcare · Biotechnology · Small-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. Xeris Biopharma Holdings, Inc. is an average business by our measures, its shares look cheap compared with other stocks, and its share price has been doing well.
Value77
Quality55
Price trend92
Overall73
16 of 2764rank among the US stocks we score (our core model buys the top 15)
99%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$291.8M
Sales growthchange from the year before+43.7%
Operating marginshare of sales left after running the business8.5%
Net marginshare of sales kept as profit0.2%
Return on invested capitalprofit made on each $100 put into the business8.4%
Return on equityprofit vs. shareholders' accounting value4.0%
Debt / equitydebt vs. shareholders' accounting value16.10
Change in share countnegative = the company is buying back its shares+17.7%

Insider trades, last 90 days

2 insiders sold $254K (all under pre-arranged plans) on the open market.

Hecht BethSee RemarksSold (plan)Aug 316,666 shat $8.01 · $134K
McCulloch KevinSee RemarksSold (plan)Aug 315,000 shat $8.02 · $120K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy